About Trius Therapeutics
Trius Therapeutics is a company based in San Diego (United States) founded in 2004 was acquired by Cubist Pharmaceuticals in July 2013. Trius Therapeutics has raised $69.16 million across 4 funding rounds from investors including Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated. Trius Therapeutics offers products and services including LLC Formation Guides and Service Reviews. Trius Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter San Diego, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$69.16 M (USD)
in 4 rounds
-
Latest Funding Round
$30.16 M (USD), Post-IPO
Jun 03, 2011
-
Investors
Kleiner Perkins
& 6 more
-
Employee Count
Not available
-
Acquired by
Cubist Pharmaceuticals
(Jul 30, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Trius Therapeutics
Trius Therapeutics offers a comprehensive portfolio of products and services, including LLC Formation Guides and Service Reviews.
Provides step-by-step instructions for starting LLCs in US states
Offers evaluations of legal and business formation services
Funding Insights of Trius Therapeutics
Trius Therapeutics has successfully raised a total of $69.16M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.16 million completed in June 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Trius Therapeutics
Trius Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked | |
|
VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Trius Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Trius Therapeutics
Investment portfolio details for Trius Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Trius Therapeutics
Detailed financials for Trius Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trius Therapeutics Comparisons
Peer comparison for Trius Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Trius Therapeutics
Trius Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of Trius Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trius Therapeutics
Complete news archive for Trius Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trius Therapeutics
Trius Therapeutics was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Trius Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Trius Therapeutics is a funded company, having raised a total of $69.16M across 4 funding rounds to date.
Trius Therapeutics focuses on the discovery, development, and commercialization of antibiotics for serious infections. It developed tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also developed GyrBParE, which are in preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such as ciprofloxacin It was acquired by Cubist Pharmaceuticals in July 2013.
Trius Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Trius Therapeutics offers LLC Formation Guides and Service Reviews.
Trius Therapeutics has 7 investors. Key investors include Kleiner Perkins, Cubist Pharmaceuticals, FinTech Global Incorporated, Sofinnova, and InterWest.